AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
机构：[1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[2]Department of Pathology, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[3]Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[4]Department of Ultrasound, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[5]Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[6]Department of Urology and Comprehensive Cancer Center, University of California Davis, Sacramento, California
Science and Technology Support Program
of Sichuan Province, Grant/Award Number:
2015SZ0230‐3; 1.3.5 project for disciplines
of excellence, West China Hospital, Sichuan
University; National Natural Science
Foundation of China, Grant/Award Numbers:
81272820, 81672547, 81872108, 81402110,
81872107
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类|3 区医学
小类|3 区内分泌学与代谢3 区泌尿学与肾脏学
最新[2023]版：
大类|3 区医学
小类|3 区泌尿学与肾脏学4 区内分泌学与代谢
第一作者：
第一作者机构：[1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China[2]Department of Pathology, West China Hospital, Sichuan University, Chengdu, China[*1]Department of Pathology, West China Hospital, Sichuan University, 610041 Chengdu, China.[*2]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 610041 Chengdu, China.
推荐引用方式(GB/T 7714)：
Zhao Jinge,Zhang Mengni,Liu Jiandong,et al.AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.[J].The Prostate.2019,79(13):1553-1562.doi:10.1002/pros.23875.
APA：
Zhao Jinge,Zhang Mengni,Liu Jiandong,Liu Zhenhua,Shen Pengfei...&Zeng Hao.(2019).AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy..The Prostate,79,(13)
MLA：
Zhao Jinge,et al."AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.".The Prostate 79..13(2019):1553-1562
